Jamie Bludsworth-Jones, DO
Internal Medicine · Enterprise, ALNPI 1801020029
Payments from drug & device makers
Across 311 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$549
- AstraZeneca$400
- Johnson & Johnson$394
- GSK$377
- Lilly USA, LLC$302
- Corium, LLC$285
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,714100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $549 |
| AstraZeneca | 26 | $400 |
| Johnson & Johnson | 42 | $394 |
| GSK | 24 | $377 |
| Lilly USA, LLC | 27 | $302 |
| Corium, LLC | 12 | $285 |
| AbbVie(2 entities) | 14 | $277 |
| Pfizer | 23 | $266 |
| Bayer | 15 | $249 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $220 |
| Astellas Pharma US Inc | 10 | $208 |
| Phathom Pharmaceuticals, Inc. | 4 | $157 |
| Novartis | 8 | $127 |
| Boehringer Ingelheim | 14 | $111 |
| Amgen(2 entities) | 8 | $109 |
| Teva Pharmaceuticals USA, Inc. | 8 | $98 |
| Viiv Healthcare Company | 1 | $93 |
| Medtronic | 1 | $84 |
| Otsuka America Pharmaceutical, Inc. | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Radius Health, Inc. | 3 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $50 |
| Baxter Healthcare | 1 | $47 |
| Dexcom, Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$125
How this compares
$4,725 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 170 | $195,870 |
| EliquisApixaban | 141 | $142,123 |
| FarxigaDapagliflozin Propanediol | 115 | $110,581 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 126 | $108,308 |
| MounjaroTirzepatide | 95 | $105,429 |
| TrulicityDulaglutide | 58 | $62,855 |
| JardianceEmpagliflozin | 61 | $49,608 |
| XareltoRivaroxaban | 50 | $39,122 |
| MyrbetriqMirabegron | 42 | $35,250 |
| LinzessLinaclotide | 42 | $35,159 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $26,009 |
| JanuviaSitagliptin Phosphate | 25 | $25,556 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $24,920 |
| Spiriva RespimatTiotropium Bromide | 27 | $19,891 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $19,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $549 | $195,870170 claims |
| Lilly USA, LLCMounjaro, Trulicity | $302 | $168,284153 claims |
| PfizerEliquis | $266 | $142,123141 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $377 | $131,760162 claims |
| AstraZenecaFarxiga, Symbicort | $400 | $121,442145 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Tradjenta | $111 | $106,034132 claims |
| Johnson & JohnsonXarelto | $394 | $39,12250 claims |
| Astellas Pharma US IncMyrbetriq | $208 | $35,25042 claims |
| AbbVieLinzess | $277 | $35,15942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Enterprise
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.